Table 3

Telomere length measured in patients with BMF

SubgroupNo. of patients (families)
No. of patients with telomeres ≤ 1st percentile (%)
WUMCReferred*All
DC 1 (1) 18 (9) 19 (10) 19 (100) 
DBA 9 (6) 25 (22) 34 (28) 5 (14.7) 
SDS 5 (5) 0 (0) 5 (5) 1 (20) 
MDS 14 (14) 3 (3) 17 (16) 3 (17.6) 
PNH 23 (23) 2 (2) 25 (25) 4 (16) 
AA 33 (32) 24 (21) 57 (53) 16 (28.1) 
IBMF 2 (2) 1 (1) 3 (3) 1 (33.3) 
Total 87 (83) 73 (58) 160 (139) 49 (30.6) 
SubgroupNo. of patients (families)
No. of patients with telomeres ≤ 1st percentile (%)
WUMCReferred*All
DC 1 (1) 18 (9) 19 (10) 19 (100) 
DBA 9 (6) 25 (22) 34 (28) 5 (14.7) 
SDS 5 (5) 0 (0) 5 (5) 1 (20) 
MDS 14 (14) 3 (3) 17 (16) 3 (17.6) 
PNH 23 (23) 2 (2) 25 (25) 4 (16) 
AA 33 (32) 24 (21) 57 (53) 16 (28.1) 
IBMF 2 (2) 1 (1) 3 (3) 1 (33.3) 
Total 87 (83) 73 (58) 160 (139) 49 (30.6) 

WUMC indicates Washington University Medical Center; DC, dyskeratosis congenita; DBA, Diamond Blackfan syndrome; SDS, Shwachman-Diamond syndrome; MDS, myelodysplastic syndrome; PNH, paroxysmal nocturnal hemoglobinuria; AA, aplastic anemia; and IBMF, inherited bone marrow failure.

*

Patients enrolled through institutions outside Washington University.

Close Modal

or Create an Account

Close Modal
Close Modal